You are here


20 - 06 - 2018

Protection from the consequences of liver cirrhosis

Aleglitazar shows encouraging results for the treatment of complications related to liver cirrhosis in a rat model.

Most of the medical complications associated with liver cirrhosis come from the hypertension of the vein that feeds the liver from the digestive system: the portal vein. The liver, intestine and spleen are affected by this hypertension.
Anti-hypertensive beta-blockers are widely used to treat this hypertension but they have limited effectiveness and cause side effects.


Researchers have studied in a rat model of cirrhosis, the effect of aleglitazar, a PPARa / y agonist that can potentially act on the liver, intestine and spleen.


They administered the product to the animals for twenty-one days and observed:

-       in the liver the suppression of fibrogenesis and angiogenesis and the  disappearance of the vasoconstrictor response

-        in the spleen a reduction in neoangiogenesis, vasodilatation and venous shunts

-       at the level of the intestine a reduction of the lesions of the intestinal mucosa and hyperpermeability.





These results can be attributed to the anti-inflammatory activity of aleglitazar and its anti-TNF alpha action.
They encourage the evaluation of this product in the treatment of complications related to hepatic cirrhosis in patients.